
CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition comprising a therapeutically effective amount compound (**1**)



(**1**)

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof, wherein the cancer is a midline glioma having a histone H3 K27M mutation.

2. The use according to claim **1**, wherein the midline glioma is selected from the group consisting of a diffuse intrinsic pontine glioma, a diffuse midline glioma, a spinal cord glioma, a thalamic glioma, a brainstem glioma, and a cerebellar glioma.

3. The use according to claim **1**, wherein the midline glioma is not a spinal cord tumor.

4. The use according to claim **1**, wherein the histone H3 K27M mutation in the midline glioma is H3.3 K27M or H3.1 K27M.

5. The use according to claim **1**, wherein the histone H3 K27M mutation in the midline glioma is in one or more histone genes selected from *H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I,* or *HIST1H3J*.

6. The use according to claim **1**, wherein in cancerous tissue DRD2 is overexpressed, DRD5 is underexpressed, or both.

7. The use according to claim **1**, wherein the subject is a human.

8. The use according to claim **1**, wherein the subject is a domesticated pet.

9. The use according to claim **1**, wherein the subject is a pediatric subject.

10. The use according to claim **1**, wherein the pharmaceutically acceptable salt is a di-hydrochloride salt.